Answers are grounded in this paper and cite their sources.
Aims To describe healthcare resource utilization (HCRU) and associated costs after initiation of injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy by adult patients with type 2 diabetes (T2D) in the prospective, observational, 24-month TROPHIES study in France, Germany, and Italy.
No takes yet. Share an insight, caveat, or question.
Barrett et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: